Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

扫码查看

原文链接

NETL
NSTL
维普
万方数据

外文摘要：Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved remarkable success in treating multiple types of cancer.However,owing to the heterogeneity of tumors and individual immune systems,PD-L 1/PD-1 blockade still shows slow response rates in controlling malignancies in many patients.Accumulating evidence has shown that an effective response to anti-PD-L1/anti-PD-1 therapy requires establishing an integrated immune cycle.Damage in any step of the immune cycle is one of the most important causes of immunotherapy failure.Impairments in the immune cycle can be restored by epigenetic modification,including reprogramming the environment of tumor-associated immunity,eliciting an immune response by increasing the presentation of tumor antigens,and by regulating T cell trafficking and reactivation.Thus,a rational combination of PD-L 1/PD-1 blockade and epigenetic agents may offer great potential to retrain the immune system and to improve clinical outcomes of checkpoint blockade therapy.

外文关键词：

Epigenetic regulationImmune cyclePD-L1/PD-1 blockadeCancerImmunotherapy

作者：

Xi Chen、Xiaohui Pan、Wenxin Zhang、Hongjie Guo、Shuyuan Cheng、Qiaojun He、Bo Yang、Ling Ding

展开 >

作者单位：

Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology,College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

基金：

National Natural Science Foundation of China for Distinguished Young ScholarNational Natural Science Foundation of China

项目编号：

No81625024 to Bo YangNo81773754 to Ling Ding

出版年：

2020

药学学报(英文版)

CSTPCDCSCDSCI

ISSN：

年,卷(期)：2020.10(5)

被引量15
参考文献量2